Mirum Pharmaceuticals, Inc.
San Mateo, CA
- UEI
- U8E2HFXRE9X3
- CAGE
- 959U9
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 989 E Hillsdale Blvd #300, San Mateo, CA 94404, USA
- Website
- mirumpharma.com
- Founded
- 2018
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $1,139 |
| FY2025 | $458,451 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $1,139 |
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Ctesi (chenodiol) 250MG drug | Veterans Integrated Service Network 10 (VHA) | $227,874 | |
| Pharmacy pharmaceutical drug | Veterans Integrated Service Network 10 (VHA) | $231,717 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Ascendis Pharma, Inc. | — | 325412 Pharmaceutical Preparation Manufacturing |
| Soleno Therapeutics Inc. | Redwood City, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| U.s. Division | Rockville, MD | 424210 Drugs and Druggists' Sundries Merchant Wholesalers |
| Biogen U.s. Corporation | Cambridge, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Alexion Pharmaceuticals Inc. | Boston, MA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Mirum Pharmaceuticals, Inc. is a for-profit pharmaceutical manufacturer specializing in rare disease treatments, based in San Mateo, California. The company is registered in the System for Award Management (SAM) and focuses on developing innovative pharmaceutical therapies, with a strategic emphasis on addressing complex medical conditions. Through its federal contract portfolio, Mirum provides specialized pharmaceutical products primarily to the U.S. Department of Veterans Affairs (VA), delivering targeted drug treatments for specific medical conditions.
The company has been awarded federal contracts specifically for pharmaceutical drug delivery, with recent contracts focusing on specific medications like CTESI (CHENODIOL) 250MG and other pharmacy pharmaceutical drugs. These contracts are primarily firm fixed-price purchase orders with the VA, specifically targeting Veterans Integrated Service Network 10 and 12. The contract awards have ranged from $226,734.65 to $231,716.56, with completion dates extending to September 30, 2025. None of the contract awards utilized set-aside designations, indicating open competition for the procurement. The contracts demonstrate Mirum's capability to provide specialized pharmaceutical products directly to federal healthcare agencies, with a particular focus on supporting the healthcare needs of military veterans.
Mirum Pharmaceuticals holds multiple federal contract indefinite delivery vehicles (IDVs) under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). These include a single-award Blanket Purchase Agreement (BPA) valued at $1,125,000 with a performance period through May 2026, specifically for the drug Livmarli used to treat Alagille syndrome. The company also maintains a multiple-award contract valued at $225,000 and a prior interim agreement of $25,000, all under the same GSA schedule. These contract vehicles enable VA medical centers and other federal agencies to efficiently purchase Mirum's pharmaceutical products, with a strategic approach to delivering innovative therapies for rare diseases to support federal healthcare requirements.
Quick answers
Is Mirum Pharmaceuticals, Inc. registered in SAM.gov?
Yes. Mirum Pharmaceuticals, Inc.'s SAM.gov registration is active through March 4, 2027.
Which contract vehicles does Mirum Pharmaceuticals, Inc. hold?
Mirum Pharmaceuticals, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Mirum Pharmaceuticals, Inc. received in federal contracts?
Federal contracts obligated $458,451 to Mirum Pharmaceuticals, Inc. in fiscal year 2025 and $459,591 in fiscal years 2023 through 2027.
How does Mirum Pharmaceuticals, Inc. rank among federal contractors?
Mirum Pharmaceuticals, Inc. ranked #16 in PSC 3650 in FY2025.
What is Mirum Pharmaceuticals, Inc.'s most recent federal award?
Mirum Pharmaceuticals, Inc.'s most recent federal contract award is Ctesi (chenodiol) 250MG drug (36C25025P1221), from Veterans Integrated Service Network 10 (VHA), on June 10, 2025.
On GovTribe
See Mirum Pharmaceuticals, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors